1. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. (23rd February 2015) Authors: Armenia, D.; Fabeni, L.; Alteri, C.; Di Pinto, D.; Di Carlo, D.; Bertoli, A.; Gori, C.; Carta, S.; Fedele, V.; Forbici, F.; D'Arrigo, R.; Svicher, V.; Berno, G.; Pizzi, D.; Nicastri, E.; Sarmati, L.; Pinnetti, C.; Ammassari, A.; D'Offizi, G.; Latini, A. Journal: Journal of antimicrobial chemotherapy Issue: Volume 70:Number 6(2015:Jun.) Page Start: 1865 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. (19th December 2016) Authors: Armenia, D.; Di Carlo, D.; Calcagno, A.; Vendemiati, G.; Forbici, F.; Bertoli, A.; Berno, G.; Carta, S.; Continenza, F.; Fedele, V.; Bellagamba, R.; Cicalini, S.; Ammassari, A.; Libertone, R.; Zaccarelli, M.; Ghisetti, V.; Andreoni, M.; Ceccherini-Silberstein, F.; Bonora, S.; Di Perri, G. Journal: Journal of antimicrobial chemotherapy Issue: Volume 72:Number 3(2017:Mar.) Page Start: 855 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗